Transaction Information
Palisade Bio, Inc (NASDAQ: PALI) announced the closing of its underwritten public offering for gross proceeds of approximately $5 million priced at-market under Nasdaq rules.
Ladenburg Thalmann & Co. Inc. acted as sole bookrunning manager in connection with this Offering.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
The information and material presented is provided for informational purposes only and are not to be used or considered as an offer or the solicitation of an offer to sell or buy any securities mentioned herein.